Trial Profile
Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With a PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs Dostarlimab (Primary) ; Niraparib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms JASPER
- Sponsors GlaxoSmithKline; GSK; TESARO
- 24 Sep 2021 Status changed from active, no longer recruiting to completed.
- 03 Sep 2021 Results (n=38; data cutoff: 4 May 2020) assessing efficacy and safety from cohort 1 and 2 of this trial published in the Cancer
- 15 Jun 2021 Planned End Date changed from 1 Apr 2021 to 1 Jul 2021.